Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

AVIR vs OKUR: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

AVIR Wins Head-to-Head Institutional Verdict (3–1 across 6 Pillars · 5–1 Matrix Metrics)

AVIR Overall Winner 6-Pillar Tally: AVIR 3 – 1 OKUR (2 Tie) Matrix Metrics: AVIR 5 – 1 OKUR

As of Nov 20, 2026, Atea Pharmaceuticals, Inc. (AVIR) is the stronger overall head-to-head candidate over OnKure Therapeutics, Inc. (OKUR) in the Tradestie Institutional Equity Comparison Engine, winning 5–1 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Options & Positioning). AVIR carries a Unified Composite Score of 44.0/100 (HOLD) at $3.96 (N/M Forward P/E, 0.0% operating margin), whereas OKUR carries 36.0/100 (SELL) at $2.70 (N/M Forward P/E, 0.0% operating margin).

  • Technical & Structure Timing Caution: AVIR is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 37.5); meanwhile OKUR is in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 48.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About AVIR vs OKUR
AVIR NASDAQ Head-to-Head Winner
Atea Pharmaceuticals, Inc. Common Stock
Pharmaceutical Preparations
$3.96
+0.76% 1D
Market Cap $315.6M
TTM Revenue $192M
Forward P/E N/M
Beta / 30D Vol 0.96β · 48% Vol
Unified Composite Score
44.0 / 100 HOLD
Tech 30.0 Fund 51.0 Flow 67.0 Mom 68.9
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -9.8%), weak momentum, RSI 38
RSI-14: 37.5 · SMA20: $4.18 · SMA50: $4.65
OKUR NASDAQ
OnKure Therapeutics, Inc. Class A Common Stock
Pharmaceutical Preparations
$2.70
-2.17% 1D
Market Cap $113.7M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.96β · 100% Vol
Unified Composite Score
36.0 / 100 SELL
Tech 20.0 Fund 46.0 Flow 64.0 Mom 60.0
Weinstein Technical Phase Distribution · Trim / tighten stop
Price near a flattening SMA50 (slope -12.6%) with fading momentum, RSI 49
RSI-14: 48.7 · SMA20: $2.76 · SMA50: $2.67

6-Pillar Scorecard Institutional Category Breakdown (AVIR 3 – 1 OKUR)

Columns: Metric · AVIR · OKUR
1. Valuation Multiples AVIR
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 1.1x N/M
2. Growth & Scale AVIR
Revenue Growth (YoY) +295.2% +0.0%
Earnings Growth (YoY) +264.1% +0.0%
TTM Revenue (USD) $192M N/A
Market Cap $315.6M $113.7M
3. Profitability & Quality Tie
Gross Margin -74.9% N/A
Operating Margin 0.0% 0.0%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -63.2% -55.2%
4. Balance Sheet & Cash Flow OKUR
Cash Generation (TTM) -$141M -$48M
Cash Flow Margin -73.1% N/A
Net Cash / Leverage $98M Net Cash $151M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning AVIR
Options Structure Phase BREAKDOWN SURGE
Current IV / %ile 476.1% (100th %ile) 89.1% (100th %ile)
Put/Call OI Skew 8.74x (Put-Skewed) N/A
OBV Trend / Tech Phase NEUTRAL · Markdown DISTRIBUTION · Distribution
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: AVIR (5) vs OKUR (1)
Institutional Metric AVIR OKUR Criterion Row Edge
Market Capitalization
Scale
$315.6M $113.7M Larger Scale AVIR
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+295.2% +0.0% Higher Growth AVIR
Operating Margin (TTM)
Profitability
0.0% 0.0% Higher Margin Tie
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-63.2% -55.2% Higher ROE OKUR
52-Week Range Position
Momentum
29% ($3–$6) 20% ($2–$5) Stronger Trend AVIR
Beta / 30D Volatility
Risk Regime
0.96β · 48% Vol 0.96β · 100% Vol Lower Realized Risk AVIR
Unified Institutional Score
Composite Signal
44.0 / 100 (HOLD) 36.0 / 100 (SELL) Higher Composite AVIR
Trailing 12M Revenue (USD)
Operating Scale
$192M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
-74.9% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 1.1x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$141M ($98M Net Cash) -$48M ($151M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon OKUR +6.87 pp
AVIR: -2.22% · OKUR: +4.65%
3M Horizon AVIR +2.46 pp
AVIR: -28.13% · OKUR: -30.59%
6M Horizon AVIR +25.46 pp
AVIR: -10.41% · OKUR: -35.87%
1Y Horizon AVIR +27.88 pp
AVIR: +25.71% · OKUR: -2.17%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on AVIR vs OKUR. Trailing 12-month operating profitability (AVIR 0.0% vs OKUR 0.0%) and valuation multiples (AVIR N/M vs OKUR N/M Forward P/E) are benchmarked directly in Pillar 4 below.

AVIR ADR TTM Benchmark FX-Normalized USD
TTM Revenue$192M
Gross Margin-74.9%
Op. Margin0.0%
ROE / Fwd P/E-63.2% · N/M
OKUR ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-55.2% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
AVIR BREAKDOWN
54d in phase · OBV NEUTRAL
Current IV 476.1%
IV Percentile 100th %ile
Put/Call OI Skew 8.74x (Put-Skewed)
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact AVIR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
OKUR SURGE
8d in phase · OBV DISTRIBUTION
Current IV 89.1%
IV Percentile 100th %ile
Put/Call OI Skew N/A
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact OKUR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
AVIR Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $315.6M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
OKUR Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $113.7M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ AVIR vs OKUR Key Questions & Quantitative Answers

As of Nov 20, 2026, Atea Pharmaceuticals, Inc. (AVIR) is the stronger overall head-to-head candidate over OnKure Therapeutics, Inc. (OKUR) in the Tradestie Institutional Equity Comparison Engine, winning 5–1 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Options & Positioning). AVIR carries a Unified Composite Score of 44.0/100 (HOLD) at $3.96 (N/M Forward P/E, 0.0% operating margin), whereas OKUR carries 36.0/100 (SELL) at $2.70 (N/M Forward P/E, 0.0% operating margin). Technical & Structure Timing Caution: AVIR is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 37.5); meanwhile OKUR is in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 48.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

AVIR leads the Growth & Scale pillar: AVIR posts +295.2% YoY revenue growth and +264.1% YoY earnings growth on $192M TTM revenue (-74.9% gross margin, 0.0% operating margin), compared with OKUR at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, AVIR generates $192M in USD-normalized revenue versus N/A for OKUR. In operating R&D and SG&A reinvestment, AVIR deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for OKUR.

AVIR screens cheaper on headline valuation multiples. AVIR trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 1.1x EV/Revenue (-73.1% FCF margin), whereas OKUR trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against AVIR (-63.2% ROE) versus OKUR (-55.2% ROE) capital efficiency.

In options market volatility and institutional positioning, AVIR carries 476.1% implied volatility (100th %ile, Extreme (>80th %ile)), a 8.74x (Put-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (0.96β · 48% Vol realized risk). By comparison, OKUR carries 89.1% implied volatility (100th %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, DISTRIBUTION on-balance volume, and sits in a SURGE options structure phase (0.96β · 100% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.